Short Interest in GTx Inc. (GTXI) Rises By 66.5%
GTx Inc. (NASDAQ:GTXI) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 1,242,509 shares, an increase of 66.5% from the August 31st total of 746,408 shares. Based on an average daily volume of 1,200,641 shares, the short-interest ratio is presently 1.0 days. Currently, 3.1% of the shares of the company are sold short.
Shares of GTx (NASDAQ:GTXI) opened at 0.75 on Wednesday. The stock has a market cap of $106.44 million, a price-to-earnings ratio of 4.52 and a beta of 2.35. GTx has a one year low of $0.29 and a one year high of $1.17. The company has a 50-day moving average of $0.68 and a 200 day moving average of $0.64.
GTx (NASDAQ:GTXI) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. On average, equities analysts forecast that GTx will post ($0.12) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in GTx stock. BVF Inc. IL raised its position in GTx Inc. (NASDAQ:GTXI) by 3.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,512,000 shares of the biopharmaceutical company’s stock after buying an additional 348,864 shares during the period. GTx accounts for 1.4% of BVF Inc. IL’s portfolio, making the stock its 21st largest position. BVF Inc. IL owned about 8.12% of GTx worth $5,756,000 as of its most recent filing with the SEC. 10.77% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of GTx from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Jefferies Group reissued a “hold” rating and issued a $1.00 price target on shares of GTx in a report on Friday, September 9th.
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Stock Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related stocks with our FREE daily email newsletter.